ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tumor necrosis factor (TNF)"

  • Abstract Number: 2448 • 2017 ACR/ARHP Annual Meeting

    Increased Cumulative Exposure to Tumor Necrosis Factor Inhibitors Reduces Radiographic Progression in US Veterans with Rheumatoid Arthritis in Real World Clinical Practice

    Grant Cannon1, Alan R. Erickson2, Chia-Chen Teng, MS1, Tina Huynh1, Sally W. Wade3, Bradley S. Stolshek4, David Collier5, Alex Mutebi6 and Brian C. Sauer, PhD1, 1Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Wade Outcomes Research and Consulting, Salt Lake City, UT, 4Amgen, Inc., Thousand Oaks, CA, 5Amgen Inc., Thousand Oaks, CA, 6Global Health Economics, Amgen Inc., Thousand Oaks, CA

    Background/Purpose:    While tumor necrosis factor inhibitors (TNFi) have been proven to reduce progression of structural joint damage in rheumatoid arthritis (RA) in randomized clinical…
  • Abstract Number: 2450 • 2017 ACR/ARHP Annual Meeting

    Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry

    Leslie R Harrold1, Heather J. Litman2, SE Connolly3, E Alemao3, K Price3, S Kelly3, Sabrina Rebello4, W Hua2 and Joel Kremer5, 1University of Massachusetts, Worcester, MA, 2Corrona, Southborough, MA, 3Bristol-Myers Squibb, Princeton, NJ, 4Corrona, LLC, Southborough, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept than anti-CCP negativity in patients with RA1,2; however, there are no…
  • Abstract Number: 2485 • 2017 ACR/ARHP Annual Meeting

    Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events

    Hiroki Wakabayashi1, Hitoshi Inada2, Yosuke Nishioka3, Masahiro Hasegawa1,4, Kusuki Nishioka5 and Akihiro Sudo6, 1Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, 2Orthopaedic Surgery, Suzuka General Hospital, Suzuka, Japan, 3Clinical Research Institute for Rheumatic Disease, Shima, Japan, 4Mie University Graduate School of Medicine, Tsu, Japan, 5Tokyo Medical University, Shinjuku, Japan, 6Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan

    Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitors have been used to treat rheumatoid arthritis (RA) for >10 years. The outcomes has revolutionized the treatment goal…
  • Abstract Number: 75 • 2017 ACR/ARHP Annual Meeting

    Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis

    Michelle Frits1, Gary Bradwin2, Nancy A. Shadick1, Christine Iannaccone3, Michael Weinblatt1, Nader Rifai2 and Katherine P. Liao4, 1Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Laboratory Medicine, Childrens Hospital Boston, Boston, MA, 3Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Tumor necrosis factor-alpha (TNFa) is involved in the pathogenesis of RA and is increasingly being studied as a biomarker of cardiovascular disease (CVD).  While…
  • Abstract Number: 2711 • 2017 ACR/ARHP Annual Meeting

    Mucosal-Associated Invariant T Cells Are an Important Source of TNF in Rheumatoid Arthritis

    Diahann Jansen1, Elizabeth Klinken1, Hendrik Nel1, Soi Cheng Law1, Hester Koppejan2, Marjolijn Hameetman3, Ligong Liu4, Alexandra Corbett5, Sidonia Eckle5, David Fairlie4, Rene E.M. Toes6, Floris van Gaalen7, Jamie Rossjohn8,9,10, James McCluskey5 and Ranjeny Thomas1, 1The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia, 2Department of Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia, 5Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 8Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Australia, 9Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, 10Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

    Background/Purpose: CD8+ T cells have been described to comprise up to 40% of the rheumatoid arthritis (RA) synovial T cell compartment but their pathogenic function…
  • Abstract Number: 139 • 2017 ACR/ARHP Annual Meeting

    No Effect of Tumor Necrosis Factor-a Inhibitors on Renal Function in Patients with Rheumatoid Arthritis from Kobio Registry from 2012 to 2016

    Seong-Kyu Kim1, Jung-Yoon Choe2, Sung-Hoon Park3 and Hwajeong Lee2, 1Rheumatology, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), 2Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), 3Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South)

    Background/Purpose: Renal disease is prevalent in patients with rheumatoid arthritis (RA), although the precise prevalence of RA has not been determined. Increased mortality in patients…
  • Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting

    Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time

    Paul Studenic1, Stephan Blüml1, Holger Bang2, Daniela Sieghart1, Daniel Aletaha1, Helmuth Haslacher3, Josef S. Smolen1,4 and Günter Steiner1, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Orgentec Diagnostika GmbH, Mainz, Germany, 3Medical University Vienna, Department of Laboratory Medicine, Vienna, Austria, 4Department of Internal Medicine, Hietzing Hospital, Vienna, Austria

    Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…
  • Abstract Number: 515 • 2017 ACR/ARHP Annual Meeting

    Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy

    Wenlu Xiong1, Rochella A. Ostrowski2, William Adams3 and Rodney Tehrani4, 1Rheumatology, Vanderbilt University Medical Center, Nashville, TN, 2Rheumatology, Loyola University Medical Center, Maywood, IL, 3Clinical Research Office, Loyola University Medical Center, Maywood, IL, 4Rheumatology & Immunology, Loyola University Medical Center, Maywood, IL

    -      Background/Purpose:  Tumor necrosis factor (TNF) alpha, a key proinflammatory cytokine in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), has been a major target in…
  • Abstract Number: 959 • 2017 ACR/ARHP Annual Meeting

    A Disintegrin and Metalloprotease -17 Is Overexpressed on Rheumatoid Arthritis Osteoblasts and Is Regulated with TNF-α Stimulation

    Hidekazu Furuya, Takeo Isozaki, Shinichiro Nishimi, Airi Nishimi, Takahiro Tokunaga, Kuninobu Wakabayashi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan

    Background/Purpose: A disintegrin and metalloprotease family proteins (ADAMs) have been reported to be involved in a number of inflammatory conditions. We have previously reported a…
  • Abstract Number: 973 • 2017 ACR/ARHP Annual Meeting

    IL-6 and TNF-a Cooperate to Modulate the Cell Cycle of RA-Fibroblast-like Synoviocytes Via Cyclin Dependent Kinase Inhibitors

    Kenta Kaneshiro1, Kohsuke Yoshida1, Ayako Nakai1, Kohjin Suzuki1, Koto Uchida1, Teppei Hashimoto2, Yoshiko Kawasaki3, Natsuko Nakagawa4, Koji Tateishi5, Nao Shibanuma6, Yoshitada Sakai7 and Akira Hashiramoto1, 1Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan, 2Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, 3The Center of Rheumatic Diseases, Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, 4Department of Orthopaedic Surgery, Konan-Kakogawa Hospital, Kakogawa, Japan, 5Orthpaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, 6Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, 7Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

    Background/Purpose: IL-6 and TNF-α play an important role in the pathogenesis of RA, and the proliferation of RA-synoviocytes (FLS) is controlled by cell cycle regulators…
  • Abstract Number: 1036 • 2017 ACR/ARHP Annual Meeting

    Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis

    Patrick R. Wood1, Evan Manning2, Joshua Baker3, Grant Cannon4, Lisa Davis5, Bryant R. England6, Ted R. Mikuls7 and Liron Caplan8, 1Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2University of Colorado School of Medicine, Aurora, CO, 3Rheumatology, University of Pennsylvania, Philadelphia, PA, 4Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 5Div of Rheumatology, Denver Health, Denver, CO, 6Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, 7Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 8Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance.  Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis)…
  • Abstract Number: 1415 • 2017 ACR/ARHP Annual Meeting

    TNF-Induced IRF1 Is Critical for the Inflammatory Gene Expression in Fibroblast-like Synoviocytes

    Michael Bonelli1, Karolina von Dalwigk2, Birgit Niederreiter1, Thomas Pap3, Josef S. Smolen4, Hans Peter Kiener1 and Thomas Karonitsch1, 1Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Institute of Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, 4Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria

    Background/Purpose: Fibroblast-like synoviocytes (FLS) are increasingly recognised as major pathogenic cells in synovial inflammation of patients with Rheumatoid Arthritis (RA). In response to pro-inflammatory stimuli,…
  • Abstract Number: 652 • 2016 ACR/ARHP Annual Meeting

    The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy

    Daniel Erhardt1, Brian C Sauer2, Chia-Chen Teng2, Ted R. Mikuls3, Jeffrey R. Curtis4 and Grant W. Cannon2, 1Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 3Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: We recently reported that real-world persistence in Veteran’s Affairs (VA) patients was lower in Rheumatoid arthritis (RA) patients receiving triple therapy [methotrexate (MTX), sulfasalazine…
  • Abstract Number: 921 • 2016 ACR/ARHP Annual Meeting

    The Anti-IL-17A Antibody Secukinumab (Cosentyx®, AIN457) Diminishes the Expression of the NFκB Pathway Modulator Iκbζ

    Robert Hennze1, Thomas Schlitt1, Thomas Peters1, Irina Koroleva2, Rebecca Torene2, Xiaoyu Jiang3, Marija Curcic Djuric1, Anis Mir1, Frank Kolbinger1 and Christine Huppertz1, 1Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland, 2Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, 3Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambdrige, MA

    Background/Purpose:   In order to better understand the IL-17A signaling pathway we have analyzed the effects of IL-17A in human primary synovial fibroblasts (SF), a…
  • Abstract Number: 1568 • 2016 ACR/ARHP Annual Meeting

    Microrna-17 Suppresses TNF-α Signaling By Reducing TRAF2 and cIAP2 Association in Rheumatoid Arthritis Synovial Fibroblasts

    Nahid Akhtar1, Anil Singh2 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Washington State University, College of Pharmacy, Spokane, WA

    Background/Purpose:   TNF-α is a major cytokine implicated in rheumatoid arthritis (RA) and its expression has shown to be regulated at transcriptional and posttranscriptional levels.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology